M
Malika Ranjan
Publications - 4
Citations - 68
Malika Ranjan is an academic researcher. The author has contributed to research in topics: Gallbladder cancer & Gallbladder. The author has an hindex of 2, co-authored 4 publications receiving 41 citations.
Papers
More filters
Journal ArticleDOI
Drug-sensitive FGFR3 mutations in lung adenocarcinoma
Pratik Chandrani,Kumar Prabhash,Kumar Prabhash,Ratnam Prasad,Vidyalakshmi Sethunath,Malika Ranjan,Prajish Iyer,Jyotirmoi Aich,Hemant Dhamne,D.N. Iyer,Pawan Upadhyay,B. Mohanty,P. Chandna,Rajiv Kumar,Amit Joshi,Vanita Noronha,V.M. Patil,Anant Ramaswamy,Ashay Karpe,Rahul Thorat,Pradip Chaudhari,A. Ingle,Anuradha Choughule,Amit Dutt +23 more
TL;DR: The FGFR3 mutations are significantly higher in a proportion of younger patients and show a trend toward better overall survival, compared with patients lacking actionable alterations or those harboring KRAS mutations.
Journal ArticleDOI
ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer
Prajish Iyer,Shailesh V. Shrikhande,Malika Ranjan,Asim Joshi,Nilesh Gardi,Ratnam Prasad,Bhasker Dharavath,Rahul Thorat,Sameer Salunkhe,Bikram Sahoo,Pratik Chandrani,Hitesh Kore,Bhabani Mohanty,Vikram Chaudhari,Anuradha Choughule,Dhananjay Kawle,Pradip Chaudhari,Arvind Ingle,Shripad Banavali,Poonam Gera,Mukta Ramadwar,Kumar Prabhash,Savio George Barreto,Shilpee Dutt,Amit Dutt +24 more
TL;DR: Overall, besides implicating ERBB2 as an important therapeutic target under neo‐adjuvant or adjuvant settings, this work presents the first evidence that the presence of KRAS mutations may preclude gallbladder cancer patients to respond to anti‐ EGFR treatment, similar to a clinical algorithm commonly practiced to opt for anti‐EGFR treatment in colorectal cancer.
Journal ArticleDOI
Identifying cancer driver genes from functional genomics screens.
Trupti Togar,Sanket Desai,Rohit Mishra,Prachi Terwadkar,Manoj P. Ramteke,Malika Ranjan,Dhananjay Kawle,Bikram Sahoo,Ankita Pal,Pawan Upadhyay,Amit Dutt +10 more
TL;DR: DepRanker is presented as a simple yet robust package with no third-party dependencies for the identification of potential driver genes from a pooled shRNA functional genomic screen by integrating results from RNAi screens with gene expression and copy number data.
Posted ContentDOI
ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in early stage Gallbladder Cancer
Prajish Iyer,Shailesh V. Shrikhande,Malika Ranjan,Asim Joshi,Ratnam Prasad,Nilesh Gardi,Rahul Thorat,Sameer Salunkhe,Bhasker Dharavath,Bikram Sahoo,Pratik Chandrani,Hitesh Kore,Bhabani Mohanty,Vikram Chaudhari,Anuradha Choughule,Dhananjay Kawle,Pradip Chaudhari,Arvind Ingle,Shripad Banavali,Mukta Ramadwar,Kumar Prabhash,Savio George Barreto,Shilpee Dutt,Amit Dutt +23 more
TL;DR: Recurrent activating ERBB2 and KRAS somatic mutations are present in 6 and 3 of 44 early-stage rare gallbladder tumors, respectively, providing the first evidence that the presence of KRAS (G12V), but not KRas (G13D) mutation, may precludegallbladder cancer patients to respond to anti-EGFR treatment.